10,764 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Purchased by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd purchased a new position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) during the fourth quarter, HoldingsChannel reports. The firm purchased 10,764 shares of the company’s stock, valued at approximately $33,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Teacher Retirement System of Texas boosted its stake in shares of Tango Therapeutics by 35.8% during the 4th quarter. Teacher Retirement System of Texas now owns 14,544 shares of the company’s stock worth $45,000 after acquiring an additional 3,831 shares during the period. Sequoia Financial Advisors LLC acquired a new stake in Tango Therapeutics during the 4th quarter valued at $45,000. Wells Fargo & Company MN boosted its position in Tango Therapeutics by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 22,292 shares of the company’s stock worth $69,000 after purchasing an additional 7,599 shares during the period. Catalina Capital Group LLC acquired a new position in shares of Tango Therapeutics in the fourth quarter valued at $82,000. Finally, Verition Fund Management LLC bought a new position in shares of Tango Therapeutics in the third quarter valued at about $247,000. Institutional investors own 78.99% of the company’s stock.

Insider Activity at Tango Therapeutics

In related news, CEO Barbara Weber sold 9,778 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the transaction, the chief executive officer now directly owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. This trade represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 24,268 shares of company stock worth $72,561 in the last ninety days. 6.30% of the stock is owned by company insiders.

Tango Therapeutics Stock Performance

Shares of TNGX stock opened at $1.41 on Friday. Tango Therapeutics, Inc. has a 52 week low of $1.11 and a 52 week high of $12.02. The company has a market capitalization of $152.43 million, a price-to-earnings ratio of -1.19 and a beta of 1.03. The company has a 50-day simple moving average of $1.96 and a 200 day simple moving average of $3.47.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The firm had revenue of $4.12 million for the quarter, compared to the consensus estimate of $7.84 million. Sell-side analysts forecast that Tango Therapeutics, Inc. will post -1.19 EPS for the current year.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.